Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche IL-12 kidney cancer trials will continue after meeting with FDA, Genetics Institute.

Executive Summary

ROCHE INTERFERON-12 TRIALS FOR KIDNEY CANCER WILL CONTINUE following meetings with FDA's Center for Biologics Evaluation & Research, Genetics Institute and clinical researchers on June 15. Roche has been conducting Phase I trials at several U.S. sites of its subcutaneous-administration, recombinant human interferon-12. Roche's IL-12 is reportedly administered once a week. The National Kidney Cancer Association sent a letter to FDA Commissioner Kessler asking that the Roche trials be continued with close monitoring of patients to watch for emergence of side effects.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026389

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel